Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy

Danilova N.V.^{1, 2} , Kalzhanov Z.R.³ , Nefedova N.A.² , Mal’kov P.G.² , Kosmas I.P.^{1, 4} , Eliseeva M.Y. ^{1, 5} , Mynbaev O.A. ^{1, 5, 6}

International Journal of Nanomedicine

Dove Medical Press Ltd.

Английский

2417-2421

Опубликовано

Внешняя ссылка

10.2147/IJN.S77186

10

2015

• ¹ International Translational Medicine and Biomodeling Research Team, MIPT Center for Human Physiology, Laboratory of Cellular and Molecular Technologies, Moscow Institute of Physics and Technology, State University, Moscow, Russian Federation
• ² Department of Physiology and Basic Pathology, Lomonosov Moscow State University, Moscow, Russian Federation
• ³ Department of Human Metabolism, Academic Unit of Reproductive and Developmental Medicine, Sheffield University, Sheffield, United Kingdom
• ⁴ Department of Obstetrics and Gynecology, Ioannina State General Hospital G Chatzikosta, Ioannina, Greece
• ⁵ Department of Obstetrics, Gynecology and Reproductive Medicine, Peoples’ Friendship University of Russia, Moscow, Russian Federation
• ⁶ Laboratory of Immunology, Moscow State University of Medicine and Dentistry named after AI Evdokimov, Moscow, Russian Federation

docetaxel; solid lipid nanoparticle; antineoplastic agent; chitosan; drug carrier; nanoparticle; taxoid; apoptosis; bone marrow progenitor cell; bone marrow suppression; breast cancer; breast feeding; cancer incidence; cancer mortality; cancer screening; cancer therapy; cause of death; cell differentiation; cell proliferation; cytotoxicity; dose response; drug potency; environmental factor; follow up; G2 phase cell cycle checkpoint; health care system; human; Letter; lifestyle modification; M phase cell cycle checkpoint; MCF 7 cell line; metastasis potential; practice guideline; risk reduction; Russian Federation; survival rate; time series analysis; trend study; Western Europe; world health organization; animal; male; Neoplasms; Animals; Antineoplastic Agents; Chitosan; Drug Carriers; Humans; Male; Nanoparticles; Neoplasms; Taxoids

19.10.2018

19.10.2018

https://repository.rudn.ru/ru/records/article/record/4586/